NCT05815862View on ClinicalTrials.gov

Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

August 20, 2025

Study Completion Date

August 20, 2025

Conditions
Advanced Lung CancerOvarian Cancer
Interventions
DRUG

AL2846 capsule

AL2846 is a multi-target tyrosine kinase inhibitor.

Trial Locations (4)

200433

Shanghai Pulmonary Hospital, Shanghai

225009

Northern Jiangsu People's Hospital, Yangzhou

410000

Hunan Cancer Hospital, Changsha

The Third Xiangya Hospital of Central South University, Changsha

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY